Aurobindo unit, Evive Biotech ink licensing pact to commercialise CIN treatment product in US Business Published: 11/26/2022 Reading time: Less than 1 min. FacebookTwitterWhatsAppLinkedinCopy URL The product, a novel dimeric G-CSF long-acting fusion protein without pegylation, is currently under late-stage review by the US Food and Drug Administration for chemotherapy-induced neutropenia (CIN). Join Our Telegram Group for Job updates & Startup news LEAVE A REPLY Cancel reply Comment: Please enter your comment! Name:* Please enter your name here Email:* You have entered an incorrect email address! Please enter your email address here Website: Save my name, email, and website in this browser for the next time I comment. FacebookTwitterWhatsAppLinkedinCopy URL Himanshi Related articles Put an end to scams: How to Protect Yourself from Electricity Bill Payment Fraud Stories of Corporates 04/20/2024 Examining the IPL’s Finances: Revealing the $6.2 Billion Financial Spectacle of the Greatest Cricket Event! Stories of Corporates 04/13/2024 Which AI Will Fight for You in the AI War? Stories of Corporates 04/11/2024 No More Registrations! OpenAI Enables Everyone to Use ChatGPT Stories of Corporates 04/06/2024 Recent articles Put an end to scams: How to Protect Yourself from Electricity Bill Payment Fraud Stories of Corporates 04/20/2024 Examining the IPL’s Finances: Revealing the $6.2 Billion Financial Spectacle of the Greatest Cricket Event! Stories of Corporates 04/13/2024 Which AI Will Fight for You in the AI War? Stories of Corporates 04/11/2024 No More Registrations! OpenAI Enables Everyone to Use ChatGPT Stories of Corporates 04/06/2024